nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—melanoma	0.411	1	CbGaD
Dabigatran etexilate—F2—leg—melanoma	0.0164	0.154	CbGeAlD
Dabigatran etexilate—F2—hindlimb—melanoma	0.0147	0.138	CbGeAlD
Dabigatran etexilate—F2—appendage—melanoma	0.0126	0.118	CbGeAlD
Dabigatran etexilate—Wound—Carmustine—melanoma	0.012	0.0585	CcSEcCtD
Dabigatran etexilate—F2—endothelium—melanoma	0.0076	0.0713	CbGeAlD
Dabigatran etexilate—F2—blood vessel—melanoma	0.00701	0.0658	CbGeAlD
Dabigatran etexilate—F2—neck—melanoma	0.00501	0.0471	CbGeAlD
Dabigatran etexilate—CES1—neck—melanoma	0.0046	0.0432	CbGeAlD
Dabigatran etexilate—CES2—eye—melanoma	0.00416	0.039	CbGeAlD
Dabigatran etexilate—CES2—retina—melanoma	0.00412	0.0387	CbGeAlD
Dabigatran etexilate—Haemorrhage intracranial—Temozolomide—melanoma	0.00409	0.02	CcSEcCtD
Dabigatran etexilate—F2—eye—melanoma	0.00373	0.035	CbGeAlD
Dabigatran etexilate—CES2—skin of body—melanoma	0.00362	0.034	CbGeAlD
Dabigatran etexilate—Musculoskeletal pain—Vemurafenib—melanoma	0.00332	0.0162	CcSEcCtD
Dabigatran etexilate—CES2—mammalian vulva—melanoma	0.0033	0.031	CbGeAlD
Dabigatran etexilate—Cerebral haemorrhage—Carmustine—melanoma	0.00313	0.0153	CcSEcCtD
Dabigatran etexilate—Oesophageal ulcer—Docetaxel—melanoma	0.00306	0.0149	CcSEcCtD
Dabigatran etexilate—Cerebral haemorrhage—Temozolomide—melanoma	0.00303	0.0148	CcSEcCtD
Dabigatran etexilate—NQO2—mammalian vulva—melanoma	0.00295	0.0277	CbGeAlD
Dabigatran etexilate—Transaminases increased—Carmustine—melanoma	0.00285	0.0139	CcSEcCtD
Dabigatran etexilate—Thrombosis—Carmustine—melanoma	0.00245	0.012	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Vemurafenib—melanoma	0.00238	0.0116	CcSEcCtD
Dabigatran etexilate—CES2—head—melanoma	0.00236	0.0222	CbGeAlD
Dabigatran etexilate—F2—head—melanoma	0.00212	0.0199	CbGeAlD
Dabigatran etexilate—NQO2—head—melanoma	0.00211	0.0198	CbGeAlD
Dabigatran etexilate—CES1—head—melanoma	0.00194	0.0182	CbGeAlD
Dabigatran etexilate—Hyperbilirubinaemia—Temozolomide—melanoma	0.00184	0.00901	CcSEcCtD
Dabigatran etexilate—Infestation—Vemurafenib—melanoma	0.00184	0.00897	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Vemurafenib—melanoma	0.00184	0.00897	CcSEcCtD
Dabigatran etexilate—Hepatic enzyme increased—Temozolomide—melanoma	0.00177	0.00867	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Temozolomide—melanoma	0.0017	0.0083	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Dactinomycin—melanoma	0.00169	0.00828	CcSEcCtD
Dabigatran etexilate—CES2—lymph node—melanoma	0.00165	0.0155	CbGeAlD
Dabigatran etexilate—Oedema peripheral—Vemurafenib—melanoma	0.00162	0.00793	CcSEcCtD
Dabigatran etexilate—Haemoglobin decreased—Docetaxel—melanoma	0.00162	0.00792	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Vemurafenib—melanoma	0.00162	0.00792	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Vemurafenib—melanoma	0.00153	0.00748	CcSEcCtD
Dabigatran etexilate—ABCB1—blood vessel—melanoma	0.00151	0.0141	CbGeAlD
Dabigatran etexilate—Angiopathy—Vemurafenib—melanoma	0.0015	0.00731	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Vemurafenib—melanoma	0.00149	0.00726	CcSEcCtD
Dabigatran etexilate—NQO2—lymph node—melanoma	0.00148	0.0139	CbGeAlD
Dabigatran etexilate—Malnutrition—Vemurafenib—melanoma	0.00143	0.00701	CcSEcCtD
Dabigatran etexilate—Back pain—Vemurafenib—melanoma	0.00139	0.00678	CcSEcCtD
Dabigatran etexilate—CES1—lymph node—melanoma	0.00136	0.0128	CbGeAlD
Dabigatran etexilate—Chest discomfort—Docetaxel—melanoma	0.00126	0.00616	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Carmustine—melanoma	0.00126	0.00616	CcSEcCtD
Dabigatran etexilate—Cough—Vemurafenib—melanoma	0.00125	0.00612	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Dactinomycin—melanoma	0.00124	0.00607	CcSEcCtD
Dabigatran etexilate—Bone disorder—Docetaxel—melanoma	0.00123	0.00604	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Bleomycin—melanoma	0.00123	0.006	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Docetaxel—melanoma	0.00123	0.00599	CcSEcCtD
Dabigatran etexilate—Arthralgia—Vemurafenib—melanoma	0.00122	0.00597	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00121	0.00593	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00121	0.00592	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Docetaxel—melanoma	0.00118	0.00576	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Vemurafenib—melanoma	0.00117	0.00572	CcSEcCtD
Dabigatran etexilate—Dysphagia—Dactinomycin—melanoma	0.00116	0.00569	CcSEcCtD
Dabigatran etexilate—Infection—Vemurafenib—melanoma	0.00116	0.00569	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Carmustine—melanoma	0.00116	0.00568	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Vemurafenib—melanoma	0.00115	0.00561	CcSEcCtD
Dabigatran etexilate—Skin disorder—Vemurafenib—melanoma	0.00114	0.00556	CcSEcCtD
Dabigatran etexilate—Pneumonia—Bleomycin—melanoma	0.00112	0.00547	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Bleomycin—melanoma	0.0011	0.00536	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Temozolomide—melanoma	0.0011	0.00536	CcSEcCtD
Dabigatran etexilate—Hypotension—Vemurafenib—melanoma	0.00109	0.00535	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Bleomycin—melanoma	0.00109	0.00533	CcSEcCtD
Dabigatran etexilate—Dysphagia—Carmustine—melanoma	0.00109	0.00532	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Temozolomide—melanoma	0.00107	0.00525	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00107	0.00521	CcSEcCtD
Dabigatran etexilate—Haematuria—Bleomycin—melanoma	0.00106	0.00518	CcSEcCtD
Dabigatran etexilate—Dysphagia—Temozolomide—melanoma	0.00105	0.00514	CcSEcCtD
Dabigatran etexilate—Pneumonia—Dactinomycin—melanoma	0.00104	0.0051	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Docetaxel—melanoma	0.00102	0.00498	CcSEcCtD
Dabigatran etexilate—Bronchitis—Temozolomide—melanoma	0.00101	0.00495	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vemurafenib—melanoma	0.00101	0.00494	CcSEcCtD
Dabigatran etexilate—Fatigue—Vemurafenib—melanoma	0.00101	0.00493	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Bleomycin—melanoma	0.001	0.0049	CcSEcCtD
Dabigatran etexilate—Constipation—Vemurafenib—melanoma	0.001	0.00489	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Bleomycin—melanoma	0.000999	0.00488	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Temozolomide—melanoma	0.000978	0.00478	CcSEcCtD
Dabigatran etexilate—Pneumonia—Carmustine—melanoma	0.000977	0.00477	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Carmustine—melanoma	0.000944	0.00461	CcSEcCtD
Dabigatran etexilate—Pneumonia—Temozolomide—melanoma	0.000944	0.00461	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Temozolomide—melanoma	0.000938	0.00459	CcSEcCtD
Dabigatran etexilate—Infestation—Temozolomide—melanoma	0.000938	0.00459	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Temozolomide—melanoma	0.000912	0.00446	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Docetaxel—melanoma	0.000893	0.00436	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Temozolomide—melanoma	0.000887	0.00434	CcSEcCtD
Dabigatran etexilate—Sinusitis—Temozolomide—melanoma	0.00088	0.0043	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Carmustine—melanoma	0.000876	0.00428	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Carmustine—melanoma	0.000872	0.00426	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vemurafenib—melanoma	0.000863	0.00422	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Carmustine—melanoma	0.000859	0.0042	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Carmustine—melanoma	0.000857	0.00419	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Temozolomide—melanoma	0.000847	0.00414	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Temozolomide—melanoma	0.000842	0.00412	CcSEcCtD
Dabigatran etexilate—Asthenia—Vemurafenib—melanoma	0.00084	0.00411	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Temozolomide—melanoma	0.000832	0.00407	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Temozolomide—melanoma	0.00083	0.00406	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Docetaxel—melanoma	0.00083	0.00405	CcSEcCtD
Dabigatran etexilate—Pruritus—Vemurafenib—melanoma	0.000828	0.00405	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Temozolomide—melanoma	0.000828	0.00405	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Temozolomide—melanoma	0.000826	0.00404	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.00081	0.00396	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Docetaxel—melanoma	0.00081	0.00396	CcSEcCtD
Dabigatran etexilate—Anaemia—Bleomycin—melanoma	0.000803	0.00393	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vemurafenib—melanoma	0.000801	0.00392	CcSEcCtD
Dabigatran etexilate—ABCB1—retina—melanoma	0.000795	0.00746	CbGeAlD
Dabigatran etexilate—Cardiac disorder—Temozolomide—melanoma	0.000782	0.00382	CcSEcCtD
Dabigatran etexilate—Dizziness—Vemurafenib—melanoma	0.000774	0.00378	CcSEcCtD
Dabigatran etexilate—Angiopathy—Temozolomide—melanoma	0.000764	0.00373	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Temozolomide—melanoma	0.000761	0.00372	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Temozolomide—melanoma	0.000759	0.00371	CcSEcCtD
Dabigatran etexilate—Malnutrition—Carmustine—melanoma	0.000759	0.00371	CcSEcCtD
Dabigatran etexilate—Cough—Bleomycin—melanoma	0.000759	0.00371	CcSEcCtD
Dabigatran etexilate—Anaemia—Dactinomycin—melanoma	0.000749	0.00366	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Docetaxel—melanoma	0.000748	0.00365	CcSEcCtD
Dabigatran etexilate—Vomiting—Vemurafenib—melanoma	0.000745	0.00364	CcSEcCtD
Dabigatran etexilate—Chest pain—Bleomycin—melanoma	0.00074	0.00362	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Docetaxel—melanoma	0.00074	0.00361	CcSEcCtD
Dabigatran etexilate—Rash—Vemurafenib—melanoma	0.000738	0.00361	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vemurafenib—melanoma	0.000738	0.0036	CcSEcCtD
Dabigatran etexilate—Back pain—Carmustine—melanoma	0.000734	0.00359	CcSEcCtD
Dabigatran etexilate—Headache—Vemurafenib—melanoma	0.000734	0.00359	CcSEcCtD
Dabigatran etexilate—Malnutrition—Temozolomide—melanoma	0.000733	0.00358	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000729	0.00356	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Docetaxel—melanoma	0.000724	0.00354	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Docetaxel—melanoma	0.000714	0.00349	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Bleomycin—melanoma	0.000709	0.00347	CcSEcCtD
Dabigatran etexilate—Back pain—Temozolomide—melanoma	0.000709	0.00347	CcSEcCtD
Dabigatran etexilate—Infection—Bleomycin—melanoma	0.000705	0.00344	CcSEcCtD
Dabigatran etexilate—Anaemia—Carmustine—melanoma	0.000701	0.00343	CcSEcCtD
Dabigatran etexilate—Dysphagia—Docetaxel—melanoma	0.0007	0.00342	CcSEcCtD
Dabigatran etexilate—Nausea—Vemurafenib—melanoma	0.000696	0.0034	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Bleomycin—melanoma	0.000695	0.00339	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Docetaxel—melanoma	0.000688	0.00336	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Docetaxel—melanoma	0.000682	0.00333	CcSEcCtD
Dabigatran etexilate—Anaemia—Temozolomide—melanoma	0.000678	0.00331	CcSEcCtD
Dabigatran etexilate—Angioedema—Temozolomide—melanoma	0.00067	0.00327	CcSEcCtD
Dabigatran etexilate—Hypotension—Bleomycin—melanoma	0.000663	0.00324	CcSEcCtD
Dabigatran etexilate—Infection—Dactinomycin—melanoma	0.000657	0.00321	CcSEcCtD
Dabigatran etexilate—Hypertension—Carmustine—melanoma	0.000655	0.0032	CcSEcCtD
Dabigatran etexilate—Palpitations—Temozolomide—melanoma	0.000648	0.00317	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Dactinomycin—melanoma	0.000648	0.00317	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Bleomycin—melanoma	0.000646	0.00316	CcSEcCtD
Dabigatran etexilate—Chest pain—Carmustine—melanoma	0.000646	0.00316	CcSEcCtD
Dabigatran etexilate—Cough—Temozolomide—melanoma	0.00064	0.00313	CcSEcCtD
Dabigatran etexilate—ABCB1—mammalian vulva—melanoma	0.000636	0.00597	CbGeAlD
Dabigatran etexilate—Hypertension—Temozolomide—melanoma	0.000633	0.00309	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Bleomycin—melanoma	0.000632	0.00309	CcSEcCtD
Dabigatran etexilate—Pneumonia—Docetaxel—melanoma	0.000628	0.00307	CcSEcCtD
Dabigatran etexilate—Arthralgia—Temozolomide—melanoma	0.000624	0.00305	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Docetaxel—melanoma	0.000624	0.00305	CcSEcCtD
Dabigatran etexilate—Infestation—Docetaxel—melanoma	0.000624	0.00305	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00062	0.00303	CcSEcCtD
Dabigatran etexilate—Infection—Carmustine—melanoma	0.000615	0.00301	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Docetaxel—melanoma	0.000615	0.00301	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Docetaxel—melanoma	0.000612	0.00299	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Carmustine—melanoma	0.000606	0.00296	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000603	0.00295	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Temozolomide—melanoma	0.000598	0.00292	CcSEcCtD
Dabigatran etexilate—Infection—Temozolomide—melanoma	0.000595	0.00291	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Docetaxel—melanoma	0.00059	0.00288	CcSEcCtD
Dabigatran etexilate—Epistaxis—Docetaxel—melanoma	0.000589	0.00288	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Temozolomide—melanoma	0.000587	0.00287	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Temozolomide—melanoma	0.000586	0.00286	CcSEcCtD
Dabigatran etexilate—Skin disorder—Temozolomide—melanoma	0.000581	0.00284	CcSEcCtD
Dabigatran etexilate—Hypotension—Carmustine—melanoma	0.000579	0.00283	CcSEcCtD
Dabigatran etexilate—Fatigue—Dactinomycin—melanoma	0.00057	0.00279	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Carmustine—melanoma	0.000564	0.00276	CcSEcCtD
Dabigatran etexilate—Urticaria—Bleomycin—melanoma	0.000564	0.00275	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Docetaxel—melanoma	0.000563	0.00275	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Docetaxel—melanoma	0.00056	0.00274	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Docetaxel—melanoma	0.000553	0.0027	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Carmustine—melanoma	0.000552	0.0027	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Docetaxel—melanoma	0.000552	0.0027	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Docetaxel—melanoma	0.00055	0.00269	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Docetaxel—melanoma	0.000549	0.00268	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Temozolomide—melanoma	0.000545	0.00266	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—melanoma	0.000541	0.00264	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Carmustine—melanoma	0.000535	0.00261	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Temozolomide—melanoma	0.000534	0.00261	CcSEcCtD
Dabigatran etexilate—Constipation—Carmustine—melanoma	0.00053	0.00259	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Temozolomide—melanoma	0.000527	0.00257	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—melanoma	0.000523	0.00256	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Bleomycin—melanoma	0.000523	0.00255	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Docetaxel—melanoma	0.00052	0.00254	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Temozolomide—melanoma	0.000517	0.00252	CcSEcCtD
Dabigatran etexilate—Fatigue—Temozolomide—melanoma	0.000516	0.00252	CcSEcCtD
Dabigatran etexilate—Constipation—Temozolomide—melanoma	0.000512	0.0025	CcSEcCtD
Dabigatran etexilate—Asthenia—Bleomycin—melanoma	0.000509	0.00249	CcSEcCtD
Dabigatran etexilate—Angiopathy—Docetaxel—melanoma	0.000508	0.00248	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Carmustine—melanoma	0.000506	0.00247	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Docetaxel—melanoma	0.000506	0.00247	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Docetaxel—melanoma	0.000505	0.00247	CcSEcCtD
Dabigatran etexilate—Pruritus—Bleomycin—melanoma	0.000502	0.00245	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Carmustine—melanoma	0.00049	0.00239	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Temozolomide—melanoma	0.000489	0.00239	CcSEcCtD
Dabigatran etexilate—Malnutrition—Docetaxel—melanoma	0.000488	0.00238	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—melanoma	0.000487	0.00238	CcSEcCtD
Dabigatran etexilate—Urticaria—Temozolomide—melanoma	0.000475	0.00232	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—melanoma	0.000475	0.00232	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Temozolomide—melanoma	0.000473	0.00231	CcSEcCtD
Dabigatran etexilate—Back pain—Docetaxel—melanoma	0.000472	0.00231	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Carmustine—melanoma	0.000456	0.00223	CcSEcCtD
Dabigatran etexilate—ABCB1—head—melanoma	0.000455	0.00427	CbGeAlD
Dabigatran etexilate—Diarrhoea—Dactinomycin—melanoma	0.000453	0.00221	CcSEcCtD
Dabigatran etexilate—Vomiting—Bleomycin—melanoma	0.000451	0.0022	CcSEcCtD
Dabigatran etexilate—Anaemia—Docetaxel—melanoma	0.000451	0.0022	CcSEcCtD
Dabigatran etexilate—Rash—Bleomycin—melanoma	0.000447	0.00219	CcSEcCtD
Dabigatran etexilate—Dermatitis—Bleomycin—melanoma	0.000447	0.00218	CcSEcCtD
Dabigatran etexilate—Asthenia—Carmustine—melanoma	0.000444	0.00217	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Temozolomide—melanoma	0.000441	0.00215	CcSEcCtD
Dabigatran etexilate—Syncope—Docetaxel—melanoma	0.000437	0.00214	CcSEcCtD
Dabigatran etexilate—Palpitations—Docetaxel—melanoma	0.000431	0.00211	CcSEcCtD
Dabigatran etexilate—Asthenia—Temozolomide—melanoma	0.000429	0.0021	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Docetaxel—melanoma	0.000429	0.00209	CcSEcCtD
Dabigatran etexilate—Cough—Docetaxel—melanoma	0.000426	0.00208	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Carmustine—melanoma	0.000424	0.00207	CcSEcCtD
Dabigatran etexilate—Pruritus—Temozolomide—melanoma	0.000423	0.00207	CcSEcCtD
Dabigatran etexilate—Nausea—Bleomycin—melanoma	0.000421	0.00206	CcSEcCtD
Dabigatran etexilate—Hypertension—Docetaxel—melanoma	0.000421	0.00206	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—melanoma	0.000421	0.00206	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—melanoma	0.000417	0.00204	CcSEcCtD
Dabigatran etexilate—Arthralgia—Docetaxel—melanoma	0.000415	0.00203	CcSEcCtD
Dabigatran etexilate—Chest pain—Docetaxel—melanoma	0.000415	0.00203	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000412	0.00201	CcSEcCtD
Dabigatran etexilate—Dizziness—Carmustine—melanoma	0.00041	0.002	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Temozolomide—melanoma	0.000409	0.002	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—melanoma	0.000398	0.00194	CcSEcCtD
Dabigatran etexilate—Dizziness—Temozolomide—melanoma	0.000396	0.00193	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—melanoma	0.000395	0.00193	CcSEcCtD
Dabigatran etexilate—Vomiting—Carmustine—melanoma	0.000394	0.00192	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—melanoma	0.000393	0.00192	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—melanoma	0.000392	0.00191	CcSEcCtD
Dabigatran etexilate—Rash—Carmustine—melanoma	0.00039	0.00191	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—melanoma	0.00039	0.00191	CcSEcCtD
Dabigatran etexilate—Dermatitis—Carmustine—melanoma	0.00039	0.00191	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—melanoma	0.00039	0.0019	CcSEcCtD
Dabigatran etexilate—Headache—Carmustine—melanoma	0.000388	0.0019	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—melanoma	0.000387	0.00189	CcSEcCtD
Dabigatran etexilate—Vomiting—Temozolomide—melanoma	0.00038	0.00186	CcSEcCtD
Dabigatran etexilate—Rash—Temozolomide—melanoma	0.000377	0.00184	CcSEcCtD
Dabigatran etexilate—Dermatitis—Temozolomide—melanoma	0.000377	0.00184	CcSEcCtD
Dabigatran etexilate—Headache—Temozolomide—melanoma	0.000375	0.00183	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—melanoma	0.000372	0.00182	CcSEcCtD
Dabigatran etexilate—Nausea—Carmustine—melanoma	0.000368	0.0018	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—melanoma	0.000363	0.00177	CcSEcCtD
Dabigatran etexilate—Nausea—Temozolomide—melanoma	0.000355	0.00174	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—melanoma	0.000355	0.00173	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—melanoma	0.00035	0.00171	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—melanoma	0.000344	0.00168	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—melanoma	0.000343	0.00168	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—melanoma	0.00034	0.00166	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—melanoma	0.000325	0.00159	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—melanoma	0.000319	0.00299	CbGeAlD
Dabigatran etexilate—Abdominal pain—Docetaxel—melanoma	0.000315	0.00154	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Docetaxel—melanoma	0.000293	0.00143	CcSEcCtD
Dabigatran etexilate—Asthenia—Docetaxel—melanoma	0.000286	0.0014	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—melanoma	0.000282	0.00138	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—melanoma	0.000272	0.00133	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—melanoma	0.000263	0.00129	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—melanoma	0.000253	0.00124	CcSEcCtD
Dabigatran etexilate—Rash—Docetaxel—melanoma	0.000251	0.00123	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—melanoma	0.000251	0.00123	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—melanoma	0.000249	0.00122	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—melanoma	0.000236	0.00116	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—ALB—melanoma	6.14e-05	0.000221	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—EDN1—melanoma	6.09e-05	0.000219	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	6.06e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	6.02e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UGT2B10—melanoma	5.99e-05	0.000215	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CSF2—melanoma	5.95e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—melanoma	5.87e-05	0.000211	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR2—melanoma	5.83e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—melanoma	5.82e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	5.8e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLA2G6—melanoma	5.74e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAC2—melanoma	5.73e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—melanoma	5.72e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PRKCA—melanoma	5.71e-05	0.000205	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	5.69e-05	0.000205	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—melanoma	5.67e-05	0.000204	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WNT5A—melanoma	5.64e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFC—melanoma	5.64e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—melanoma	5.57e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HS3ST5—melanoma	5.57e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EDN1—melanoma	5.53e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CB—melanoma	5.42e-05	0.000195	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CSF2—melanoma	5.4e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—melanoma	5.36e-05	0.000193	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP17A1—melanoma	5.35e-05	0.000192	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—melanoma	5.3e-05	0.00019	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—RAC1—melanoma	5.29e-05	0.00019	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—melanoma	5.24e-05	0.000188	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PRKCA—melanoma	5.18e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CD—melanoma	5.16e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—VCAN—melanoma	5.15e-05	0.000185	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—melanoma	5.1e-05	0.000183	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF1—melanoma	5.09e-05	0.000183	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAP2K2—melanoma	5.07e-05	0.000182	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNA11—melanoma	5.05e-05	0.000182	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	4.99e-05	0.000179	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—melanoma	4.98e-05	0.000179	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—F2R—melanoma	4.95e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—FASN—melanoma	4.95e-05	0.000178	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—melanoma	4.93e-05	0.000177	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	4.91e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	4.88e-05	0.000175	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC5A5—melanoma	4.87e-05	0.000175	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RAC1—melanoma	4.8e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDNRB—melanoma	4.8e-05	0.000173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—melanoma	4.79e-05	0.000172	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	4.74e-05	0.000171	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.71e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNAQ—melanoma	4.7e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CD44—melanoma	4.7e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTK2B—melanoma	4.66e-05	0.000167	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GNA11—melanoma	4.53e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GAB2—melanoma	4.53e-05	0.000163	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	4.51e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FLT1—melanoma	4.51e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1B1—melanoma	4.5e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CB—melanoma	4.5e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—melanoma	4.47e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—melanoma	4.46e-05	0.00016	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP17A1—melanoma	4.35e-05	0.000156	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.29e-05	0.000154	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	4.28e-05	0.000154	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR4—melanoma	4.26e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HDAC2—melanoma	4.26e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FOXO4—melanoma	4.26e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.23e-05	0.000152	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—melanoma	4.23e-05	0.000152	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	4.22e-05	0.000152	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLCB4—melanoma	4.22e-05	0.000152	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GNAQ—melanoma	4.21e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—melanoma	4.18e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	4.16e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNA11—melanoma	4.11e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—melanoma	4.1e-05	0.000147	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	4.07e-05	0.000146	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—melanoma	4.06e-05	0.000146	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—FASN—melanoma	4.02e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK3—melanoma	4e-05	0.000144	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC6A11—melanoma	3.97e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIP4K2A—melanoma	3.97e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SYK—melanoma	3.96e-05	0.000142	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A5—melanoma	3.95e-05	0.000142	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—melanoma	3.93e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT3—melanoma	3.89e-05	0.00014	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NGFR—melanoma	3.89e-05	0.00014	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITGAV—melanoma	3.89e-05	0.00014	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—melanoma	3.89e-05	0.00014	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	3.87e-05	0.000139	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTAP—melanoma	3.86e-05	0.000139	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	3.85e-05	0.000139	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CD44—melanoma	3.82e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNAQ—melanoma	3.82e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK1—melanoma	3.81e-05	0.000137	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—melanoma	3.78e-05	0.000136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	3.78e-05	0.000136	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.74e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—melanoma	3.71e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.7e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	3.68e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—melanoma	3.66e-05	0.000132	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	3.64e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SOCS1—melanoma	3.6e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—melanoma	3.6e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAP2K1—melanoma	3.59e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—S100B—melanoma	3.59e-05	0.000129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—melanoma	3.57e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	3.56e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	3.55e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	3.53e-05	0.000127	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LUM—melanoma	3.44e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PHGDH—melanoma	3.44e-05	0.000124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB4—melanoma	3.43e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—melanoma	3.42e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PRKCA—melanoma	3.41e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN2B—melanoma	3.4e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ERCC2—melanoma	3.39e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPSE—melanoma	3.37e-05	0.000121	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CUBN—melanoma	3.31e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—melanoma	3.3e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD86—melanoma	3.29e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—melanoma	3.29e-05	0.000118	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EDN1—melanoma	3.27e-05	0.000117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.23e-05	0.000116	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	3.21e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CSPG4—melanoma	3.2e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BSG—melanoma	3.2e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SDHD—melanoma	3.2e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—melanoma	3.2e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSF2—melanoma	3.19e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF1—melanoma	3.19e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—melanoma	3.15e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—E2F1—melanoma	3.12e-05	0.000112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—melanoma	3.11e-05	0.000112	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPAM—melanoma	3.1e-05	0.000111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRA—melanoma	3.09e-05	0.000111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCA—melanoma	3.06e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITGB3—melanoma	3.06e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—melanoma	3.06e-05	0.00011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	3.03e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—melanoma	3.01e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—melanoma	3e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAP2K2—melanoma	2.99e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—melanoma	2.99e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	2.95e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	2.89e-05	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	2.88e-05	0.000104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—melanoma	2.86e-05	0.000103	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—melanoma	2.85e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAC1—melanoma	2.84e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PRKCA—melanoma	2.77e-05	9.97e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ERCC2—melanoma	2.75e-05	9.89e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	2.75e-05	9.88e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—melanoma	2.74e-05	9.86e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	2.73e-05	9.8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—melanoma	2.72e-05	9.78e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—melanoma	2.7e-05	9.7e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—melanoma	2.67e-05	9.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLA2G6—melanoma	2.63e-05	9.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—melanoma	2.6e-05	9.36e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—melanoma	2.58e-05	9.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FN1—melanoma	2.51e-05	9.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	2.5e-05	9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—melanoma	2.45e-05	8.81e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	2.42e-05	8.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD80—melanoma	2.4e-05	8.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—melanoma	2.4e-05	8.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KIT—melanoma	2.4e-05	8.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—melanoma	2.4e-05	8.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—melanoma	2.4e-05	8.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGF—melanoma	2.37e-05	8.52e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—VCAN—melanoma	2.36e-05	8.5e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—melanoma	2.35e-05	8.45e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—melanoma	2.32e-05	8.34e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—melanoma	2.3e-05	8.26e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.28e-05	8.19e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—melanoma	2.25e-05	8.1e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—melanoma	2.24e-05	8.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—melanoma	2.2e-05	7.89e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK1—melanoma	2.18e-05	7.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—melanoma	2.18e-05	7.85e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—melanoma	2.17e-05	7.81e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAP2K1—melanoma	2.12e-05	7.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—melanoma	2.11e-05	7.58e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—melanoma	2.1e-05	7.54e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—melanoma	2.09e-05	7.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—melanoma	2.06e-05	7.42e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—melanoma	2.05e-05	7.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.05e-05	7.35e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—melanoma	2.03e-05	7.3e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF2—melanoma	2.02e-05	7.26e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP17A1—melanoma	2e-05	7.17e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—melanoma	1.91e-05	6.87e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—melanoma	1.9e-05	6.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MDM2—melanoma	1.89e-05	6.79e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—melanoma	1.89e-05	6.78e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNA11—melanoma	1.88e-05	6.77e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—melanoma	1.86e-05	6.69e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	1.85e-05	6.64e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FASN—melanoma	1.84e-05	6.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—melanoma	1.84e-05	6.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—melanoma	1.81e-05	6.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—melanoma	1.77e-05	6.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—melanoma	1.77e-05	6.35e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—melanoma	1.75e-05	6.31e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNAQ—melanoma	1.75e-05	6.3e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CD44—melanoma	1.75e-05	6.3e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—melanoma	1.72e-05	6.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—melanoma	1.71e-05	6.13e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—melanoma	1.69e-05	6.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—melanoma	1.69e-05	6.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—melanoma	1.68e-05	6.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—melanoma	1.68e-05	6.04e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—melanoma	1.67e-05	5.99e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—melanoma	1.65e-05	5.93e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—melanoma	1.64e-05	5.91e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—melanoma	1.63e-05	5.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—melanoma	1.6e-05	5.74e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—melanoma	1.59e-05	5.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—melanoma	1.59e-05	5.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFKB1—melanoma	1.58e-05	5.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—melanoma	1.55e-05	5.57e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—melanoma	1.44e-05	5.17e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—melanoma	1.43e-05	5.16e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—melanoma	1.42e-05	5.1e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—melanoma	1.42e-05	5.09e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—melanoma	1.36e-05	4.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—melanoma	1.32e-05	4.74e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK1—melanoma	1.29e-05	4.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—melanoma	1.29e-05	4.64e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PRKCA—melanoma	1.27e-05	4.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ERCC2—melanoma	1.26e-05	4.54e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—melanoma	1.25e-05	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—melanoma	1.22e-05	4.38e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—melanoma	1.12e-05	4.03e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—melanoma	1.08e-05	3.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—melanoma	1.04e-05	3.73e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—melanoma	1.02e-05	3.67e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—melanoma	1.02e-05	3.65e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—melanoma	9.97e-06	3.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—melanoma	9.92e-06	3.57e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—melanoma	9.62e-06	3.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—melanoma	9.15e-06	3.29e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—melanoma	8.76e-06	3.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—melanoma	8.65e-06	3.11e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—melanoma	8.29e-06	2.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—melanoma	7.64e-06	2.75e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—melanoma	7.57e-06	2.72e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—melanoma	6.6e-06	2.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—melanoma	4.66e-06	1.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—melanoma	3.8e-06	1.37e-05	CbGpPWpGaD
